BB Biotech case study

The biotech advantage: BB Biotech’s sustained alpha demonstrates why investors should consider specialist funds

Published by : BB Biotech

BB Biotech investment head, Daniel Koller, discusses how his fund uncovers attractive valuations of fast-growing companies and why M&A could accelerate this year.

Click the download button to read more on BB Biotech's investment approach - an approach that sees them target 15% p.a. and rank in the top 100 dividend-yielding stocks in the Stoxx Europe 600 index.





Published:01 June 2017

Business Area: Investments

Type: Other

Rating: 1 people found this useful


Not registered?

Register with Financial Library for access to market intelligence, data and reports from leading experts.

Sign up here